| scholarly article | Q13442814 |
| P356 | DOI | 10.1074/JBC.C000147200 |
| P698 | PubMed publication ID | 10859299 |
| P2093 | author name string | Yang HY | |
| Lee MH | |||
| Hung MC | |||
| Zhou BP | |||
| P2860 | cites work | A new group of conserved coactivators that increase the specificity of AP-1 transcription factors | Q24310680 |
| Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals | Q24314293 | ||
| Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1 | Q28139243 | ||
| Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution | Q28300442 | ||
| Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers | Q28375856 | ||
| Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase | Q28613291 | ||
| Dominant-negative mutants of Grb2 induced reversal of the transformed phenotypes caused by the point mutation-activated rat HER-2/Neu | Q28678768 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Inhibitors of mammalian G1 cyclin-dependent kinases | Q29547907 | ||
| Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27 | Q29617346 | ||
| The murine gene p27Kip1 is haplo-insufficient for tumour suppression | Q33574523 | ||
| Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2 | Q33604295 | ||
| Regulation of exit from quiescence by p27 and cyclin D1-CDK4. | Q33781529 | ||
| Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation | Q33849412 | ||
| Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer | Q34415244 | ||
| Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. | Q34415250 | ||
| Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival | Q35753209 | ||
| New insights into the tumor suppression function of P27(kip1) | Q36084916 | ||
| Distinct roles for the two cGATA-1 finger domains | Q36703387 | ||
| Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. | Q40022664 | ||
| HER-2/neu-targeting gene therapy-a review | Q40442657 | ||
| Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells | Q41033252 | ||
| HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway | Q42804558 | ||
| Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu | Q42807740 | ||
| An analysis of Mek1 signaling in cell proliferation and transformation | Q42829980 | ||
| P433 | issue | 32 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 24735-24739 | |
| P577 | publication date | 2000-08-01 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. | |
| P478 | volume | 275 |
| Q36549508 | 14-3-3σ Positively Regulates p53 and Suppresses Tumor Growth |
| Q33976264 | A novel interaction between HER2/neu and cyclin E in breast cancer |
| Q35050546 | Binding of the cSH3 domain of Grb2 adaptor to two distinct RXXK motifs within Gab1 docker employs differential mechanisms |
| Q37470093 | Breast cancer adaptive resistance: HER2 and cancer stem cell repopulation in a heterogeneous tumor society |
| Q36798077 | CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity |
| Q36260630 | COP1 enhances ubiquitin-mediated degradation of p27Kip1 to promote cancer cell growth. |
| Q35010501 | Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma |
| Q43723448 | Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells |
| Q28305487 | Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity |
| Q40713599 | Correlation of p27 protein expression with HER-2/neu expression in breast cancer. |
| Q24803723 | Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer |
| Q34876386 | Detection of deregulated modules using deregulatory linked path |
| Q33929011 | Disruption of TGF-beta growth inhibition by oncogenic ras is linked to p27Kip1 mislocalization |
| Q24337925 | Distinct binding modes of two epitopes in Gab2 that interact with the SH3C domain of Grb2 |
| Q53386780 | Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells. |
| Q36677496 | ErbB receptors and epithelial-cadherin-catenin complex in human carcinomas |
| Q43800246 | ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth |
| Q34276145 | ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells |
| Q44540468 | Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway |
| Q36308092 | Expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27Kip1 in hepatocellular carcinoma |
| Q40599159 | Expression of ErbB2 enhances radiation-induced NF-kappaB activation |
| Q53687423 | Expression of p27 and c-Myc by immunohistochemistry in breast ductal cancers in African American women. |
| Q38300517 | Fingerprints of anergic T cells |
| Q36698389 | HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer |
| Q54005783 | HER-2/neu and p27Kip1 in progression of Fallopian tube carcinoma: an immunohistochemical and array comparative genomic hybridization study. |
| Q44083882 | Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells |
| Q34627179 | Hunk is required for HER2/neu-induced mammary tumorigenesis |
| Q24309891 | IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance |
| Q24300283 | Interaction and colocalization of PGP9.5 with JAB1 and p27(Kip1) |
| Q28360859 | JAB1/CSN5 and the COP9 signalosome. A complex situation |
| Q30772126 | JAB1/CSN5 interacts with the GAL4 DNA binding domain: a note of caution about two-hybrid interactions |
| Q40017171 | Jab1 is overexpressed in human breast cancer and is a downstream target for HER-2/neu. |
| Q24313377 | Jab1/CSN5, a component of the COP9 signalosome, regulates transforming growth factor beta signaling by binding to Smad7 and promoting its degradation |
| Q36493029 | NF-kappa B-mediated adaptive resistance to ionizing radiation |
| Q40436456 | Novel role for cyclin-dependent kinase 2 in neuregulin-induced acetylcholine receptor epsilon subunit expression in differentiated myotubes |
| Q34150579 | PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization |
| Q40702262 | PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest |
| Q36183877 | Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis |
| Q47114555 | Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma |
| Q35745139 | Role of the CDK inhibitor p27 (Kip1) in mammary development and carcinogenesis: insights from knockout mice |
| Q37923711 | Roles of COP9 signalosome in cancer. |
| Q34277050 | Scatter factor/hepatocyte growth factor stimulation of glioblastoma cell cycle progression through G(1) is c-Myc dependent and independent of p27 suppression, Cdk2 activation, or E2F1-dependent transcription |
| Q51111655 | The COP9 Signalosome |
| Q34763495 | The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy |
| Q28301955 | The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition |
| Q34147948 | The emerging role of the COP9 signalosome in cancer |
| Q37369189 | The multiple layers of ubiquitin-dependent cell cycle control. |
| Q34493341 | The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis |
| Q33952356 | The p42/p44 mitogen-activated protein kinase activation triggers p27Kip1 degradation independently of CDK2/cyclin E in NIH 3T3 cells. |
| Q44406747 | The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition |
| Q28354257 | Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia |
| Q28273757 | Tumor suppressor ARF inhibits HER-2/neu-mediated oncogenic growth |
| Q42827384 | p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis |
| Q34181774 | p27 as a target for cancer therapeutics |
| Q35745141 | p27 deregulation in breast cancer: prognostic significance and implications for therapy |
| Q24294568 | p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2 |
| Q34472383 | p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. |
Search more.